Serious breathing problems can occur when LYRICA is taken with other medicines that can cause severe sleepiness or decreased awareness, or when it is taken by someone who already has breathing problems. Watch for increased sleepiness or decreased breathing when starting LYRICA or when the dose is increased. Adults aged 18 years and above with neuropathic pain defined according to the International Association for the Study of Pain criteria. Neuropathic pain generally does not respond to treatment with opioid or non-steroidal anti-inflammatory drugs (NSAIDs). If you’re interested in finding an alternative to Lyrica, talk with your doctor.
- In this study, LYRICA 7 mg/kg/day and 14 mg/kg/day were compared to placebo.
- The latter findings are consistent with the presence of psychiatry-relevant phenotypes in Cacna1c heterozygous rats 71, which have reduced gene dosage.
- Examples of drugs that can cause interactions with pregabalin are listed below.
Table 1.
While studies provided information in graphical form, software (WebPlotDigitizer) was used to extract the necessary data. Additionally, for some variables measured at follow-up, there was a mix of follow-ups conducted between 4 and 8 weeks, requiring adjustments to closer follow-ups. Importantly, the lack of long-term outcomes, for example, beyond 6 months, limits our complete understanding of the long-term effects of pregabalin. Furthermore, some studies did not clearly provide patient numbers in each group, hindering comparative analysis. It was not possible to compare low-dose pregabalin adverse events with SSRI/SNRIs, and some adverse events, such as weight gain, were reported in only one study, preventing their inclusion in the meta-analysis.
Controlled Studies Of Adjunctive Therapy For Partial-Onset Seizures In Adult Patients
In these studies, 758 patients received LYRICA and 294 patients received placebo for up to 12 weeks. A majority of pregabalin-treated patients in clinical studies had adverse reactions with a buy pregabalin online uk maximum intensity of “mild” or “moderate”. In clinical trials in adults with postherpetic neuralgia, 14% of patients treated with LYRICA and 7% of patients treated with placebo discontinued prematurely due to adverse reactions.